---
schema_version: "secwatch.filing_event.v1"
accession: "0001701541-22-000017"
form_type: "8-K"
ticker: "BDTX"
cik: "0001701541"
company_name: "Black Diamond Therapeutics, Inc."
filed_at: "2022-05-11T23:59:59+00:00"
generated_at: "2026-06-25T21:06:00.618114+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Black Diamond Therapeutics Q1 net loss $25.5M; cash runway into Q3 2024; BDTX-1535 phase 1 dosed

## Summary
- Net loss $25.5M vs $30.3M Q1 2021; R&D expense $17.8M (down from $22.8M).
- Cash, equivalents, investments $179.7M; net cash used in ops $28.6M for Q1.
- First patient dosed April 2022 in Phase 1 for BDTX-1535 (EGFR inhibitor, GBM/NSCLC); clinical update in 2023.
- BDTX-4933 IND submission expected H1 2023; FGFR program candidate nomination in 2022.
- Reduced workforce ~30% in April 2022; cash runway extended into Q3 2024.

## SEC filing metadata
- accession: 0001701541-22-000017
- form_type: 8-K
- ticker: BDTX
- cik: 0001701541
- company_name: Black Diamond Therapeutics, Inc.
- filed_at: 2022-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701541/000170154122000017/0001701541-22-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701541/000170154122000017/bdtx-20220511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001701541-22-000017
- JSON: https://secwatch.observer/filing/0001701541-22-000017.json
- Plain text: https://secwatch.observer/filing/0001701541-22-000017.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.